PharmExec18h
FDA Approves Sanofi’s Qfitlia for Prophylaxis in Patients with Hemophilia A or B
Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce ...
GEN - Genetic Engineering and Biotechnology News22h
RNAi Therapeutic for Hemophilia A or B Gets FDA Approval
Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.
Taipei Times20h
Female wrestlers prepare for tournament in Japan
A legislator yesterday called for more support for female athletes and five female sumo wrestlers who are to compete in an ...
MPR21h
Qfitlia, a Novel Treatment for Hemophilia A or B, Gets FDA Approval
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
Knowridge Science Report2h
Type 2 diabetes may raise risk of certain obesity-related cancers
A major new study from the UK has found that people newly diagnosed with type 2 diabetes (T2D) face a higher risk of ...
Precision Medicine Online23h
Alnylam's Qfitlia, Siemens Antithrombin CDx Garner FDA Approval for Treating Hemophilia A/B
The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.